It Was Inevitable: FDA Inspection Delay Postpones BMS’s Liso-Cel Approval

Approval By Year-End Required For CVR Payout To Celgene Shareholders

 
• By Mandy Jackson
Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Time is running out for BMS to win liso-cel approval by a crucial deadline for former Celgene shareholders • Source: Shutterstock

More from New Products

More from Scrip